drugset

drugset / Trial / NCT00584194

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

NCT00584194 ↗

Phase 2 Completed 278 enrolled U.S. Army Medical Research and Development Command

NaSingle-groupOpen-labelPrevention

Summary

This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine

Timeline

Start: 2004-06
Primary completion: 2010-05
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TSI-GSD 200	Vaccine	1 ml	Subcutaneous

Indications